On the morning of July 3, Dizhe Pharmaceutical announced that the new drug marketing application for Schwarzer® has been officially approved by the US Food and Drug Administration for adult patients with locally advanced or metastatic non-small cell lung cancer who have progressed during or after platinum-containing chemotherapy, and have confirmed by FDA-approved kit tests to have an insertion mutation of the epidermal growth factor receptor exon 20 exon.

On the morning of July 3, Dizhe Pharmaceutical announced that the new drug marketing application for Schwarzer® has been officially approved by the US Food and Drug Administration for adult patients with locally advanced or metastatic non-small cell lung cancer who have progressed during or after platinum-containing chemotherapy, and have confirmed by FDA-approved kit tests to have an insertion mutation of the epidermal growth factor receptor exon 20 exon.